Metformin in Children With Fragile X Syndrome
Trial Parameters
Brief Summary
This study is a controlled trial of metformin in children with fragile X syndrome(FXS). The age of FXS children range from 2 to 16 years old. Participants will be randomized in a double-blind design to either drug or placebo for 6-month period. The primary objectives are to assess metformin in treatment of behavior problems, cognitive and language with fragile X syndrome.
Eligibility Criteria
Inclusion Criteria: * Genetic testing confirms the diagnosis of FXS * Participate in the study with the informed consent of the guardian * BMI\>the 3rd percentile * Not taking more than 2 therapeutic drugs * Able to receive regular follow-up visits Exclusion Criteria: * Malnutrition * Primary heart disease * Severe infection or acute clinical illness * Gastrointestinal, renal, or hepatic disease * Previous history of lactic acidosis * previous use of metformin intolerant * Use of angiotensin converting enzyme inhibitors, use of anticoagulants, vitamin B12 deficiency, alcohol consumption * Unstable systemic diseases other than FXS * Changes in clinical medication